Chemistry:N-0385
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | Ms-QFR-Kbt |
| Routes of administration | Intranasal |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C28H36N8O6S2 |
| Molar mass | 644.77 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
N-0385 is an experimental small molecule TMPRSS2-inhibitor being investigated for its potential use in the prevention and treatment of COVID-19.[1][2][3][4]
Mechanism of action
N-0385 is thought to have antiviral effects by targeting key proteins involved in the viral entry process, including TMPRSS2, ACE2, and DPP4. By interfering with the interactions between these proteins and the SARS-CoV-2 spike protein, N-0385 effectively blocks the virus from gaining access to host cells.[3][4] Additionally, N-0385 appears to modify the immune responses and inflammatory pathways associated with the infection by regulating TLR7, NLRP3, and IL-10, potentially reducing the severity of COVID-19 symptoms and reducing tissue damage associated with the infection.[4]
References
- ↑ Sankaran, Vishwam (30 March 2022). "New nasal spray found 'effective' in preventing and treating Covid in mice". https://www.independent.co.uk/news/science/nasal-spray-covid-mice-effective-b2046957.html.
- ↑ Reynolds, Sharon (11 April 2022). "Nasal antiviral blocks SARS-CoV-2 infection in mice". https://www.nih.gov/news-events/nih-research-matters/nasal-antiviral-blocks-sars-cov-2-infection-mice.
- ↑ 3.0 3.1 "A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic". Nature 605 (7909): 340–348. May 2022. doi:10.1038/s41586-022-04661-w. PMID 35344983. Bibcode: 2022Natur.605..340S.
- ↑ 4.0 4.1 4.2 "Mechanism of N-0385 blocking SARS-CoV-2 to treat COVID-19 based on molecular docking and molecular dynamics". Frontiers in Microbiology 13. October 2022. doi:10.3389/fmicb.2022.1013911. PMID 36329841.
 |  |
